<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anjali S Advani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The lymphoblastic neoplasms are classified on the basis of B cell versus T cell lineage [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>B cell lymphoblastic leukemia/lymphoma (B cell ALL/LBL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T cell lymphoblastic leukemia/lymphoma (T cell ALL/LBL)</p><p></p><p>Leukemia and lymphoma are overlapping clinical presentations of the same disease (ie, B cell ALL/LBL); diagnosis and classification do not distinguish between these entities. </p><p>B cell ALL/LBL was formerly called pro-B lymphoblastic leukemia; common precursor B-lymphoblastic leukemia; pre-B lymphoblastic leukemia; pre-pro-B lymphoblastic leukemia; common lymphoblastic leukemia; precursor B cell lymphoblastic lymphoma; precursor B cell lymphoblastic leukemia, NOS; and B cell acute lymphoblastic leukemia.</p><p>Epidemiology, clinical presentation, and diagnosis of B cell ALL/LBL is discussed here.</p><p>The following topics are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of B cell ALL/LBL (see  <a class="medical medical_review" href="/d/html/4524.html" rel="external">"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/16661.html" rel="external">"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/6245.html" rel="external">"Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and management of T cell ALL/LBL (see  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/4524.html" rel="external">"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults"</a>)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The estimated annual incidence of acute lymphoblastic leukemia (ALL) worldwide is 1 to 5 cases/100,000 population, and more than two-thirds of cases of ALL are B cell phenotype [<a href="#rid2">2,3</a>].</p><p>B cell ALL/LBL is primarily a disease of children, with three-quarters of cases occurring in children &lt;6 years old; there is a second peak of incidence in adults &gt;60 years old [<a href="#rid2">2,3</a>]. B cell ALL occurs slightly more frequently in males than females. The incidence of B cell ALL/LBL is three times higher in White people than Black people. Hispanic populations have the highest incidence of any ethnic group, and the incidence appears to be increased in certain areas of Central and South America (eg, Guatemala, Peru), for unknown reasons [<a href="#rid4">4</a>]. The Philadelphia-like signature (discussed below) is also significantly more common in patients of Hispanic ethnicity [<a href="#rid5">5</a>]. (See <a class="local">'BCR::ABL1-like (Ph-like)'</a> below.)</p><p>The cause of B cell ALL/LBL is unknown, but it may be associated with ionizing radiation and/or as-yet unidentified infectious agents [<a href="#rid6">6</a>]. True familial ALL is rare, although it has been associated with inherited mutations of <em>PAX5</em>, <em>ETV6</em>, and<em> TP53</em> [<a href="#rid7">7,8</a>]. There is an increased incidence of B cell ALL in children with Down syndrome and other constitutional disorders [<a href="#rid9">9</a>]. B cell ALL/LBL is also associated with certain single nucleotide polymorphisms in specific genes, including <em>GATA3, ARID5B, IKZF1, CEBPE </em>and<em> CDKN2A/B</em> [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes"</a> and  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis", section on 'Hematologic disorders'</a>.)</p><p class="headingAnchor" id="H3703488992"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>B cell lymphoblastic leukemia and B cell lymphoblastic lymphoma are overlapping clinical manifestations of the same disease.</p><p>Most patients have findings associated with anemia, neutropenia, and/or thrombocytopenia due to bone marrow involvement. The white blood cell count may be decreased, normal, or markedly elevated. Symptoms can include fatigue, infections, or easy/spontaneous bruising or bleeding. Bone pain or arthralgias may be prominent complaints, and constitutional symptoms (eg, fever, night sweats, unintentional weight loss) are often present, but are generally mild. Hepatomegaly, splenomegaly, and/or lymphadenopathy are present in up to half of adults. Central nervous system (CNS) involvement may be manifest as cranial neuropathies or meningeal symptoms.</p><p>The tempo of disease is variable; some patients present with symptoms that progress slowly over weeks to months, while others have a more acute presentation.</p><p>A study of 53 children with B cell LBL who were enrolled on clinical trials reported the following presenting features: osteolytic bone lesions (26 percent), skin or subcutaneous lesions (23 percent), mediastinal or pleural disease (11 percent), bone marrow (13 percent), lymph nodes alone (13 percent), gonads (6 percent), head and neck (4 percent), or kidney and digestive system (2 percent each); in addition, 43 percent had bone marrow involvement and 6 percent had CNS involvement [<a href="#rid12">12</a>].</p><p>Specific cytogenetic/genetic categories are associated with distinctive clinical presentations, as described below. (See <a class="local">'Classification of B cell ALL/LBL'</a> below.)</p><p class="headingAnchor" id="H498317"><span class="h1">PATHOLOGIC FEATURES</span></p><p class="headingAnchor" id="H5"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>The blood smear reveals lymphoblasts that may vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli  (<a class="graphic graphic_picture graphicRef83240" href="/d/graphic/83240.html" rel="external">picture 1</a>) to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli [<a href="#rid13">13</a>]. Children more commonly have smaller blasts, while adults more commonly have larger blasts [<a href="#rid13">13</a>]. A few azurophilic cytoplasmic granules may be present, but Auer rods are absent. </p><p>In tissue sections, the tumor cells are small to medium-sized with uniform appearance and scant cytoplasm  (<a class="graphic graphic_picture graphicRef83239" href="/d/graphic/83239.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef52878" href="/d/graphic/52878.html" rel="external">picture 3</a>); occasional cases have larger lymphoblasts. Nuclei are oval or convoluted with finely dispersed chromatin and indistinct or small nucleoli.</p><p class="headingAnchor" id="H1516877053"><span class="h2">Cytochemistry</span><span class="headingEndMark"> — </span>Although not required to establish the diagnosis, characteristic cytochemical findings in B cell ALL/LBL are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periodic acid-Schiff (PAS)</strong> – Lymphoblasts may reveal coarse ("chunky") granules due to the presence of glycogen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonspecific esterase (NSE)</strong> – Multifocal punctate or Golgi region pattern of staining, typically much weaker than in acute myeloid leukemias with monocytic differentiation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sudan black B</strong> – Variable positivity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloperoxidase (MPO)</strong> – No staining</p><p></p><p class="headingAnchor" id="H1047954215"><span class="h2">Flow cytometry/immunohistochemistry</span><span class="headingEndMark"> — </span>Immunophenotype, defined by flow cytometry and/or immunohistochemistry from circulating lymphoblasts, bone marrow specimen, or lymph node material, is required for the diagnosis of B cell ALL/LBL. (See <a class="local">'Evaluation and diagnosis'</a> below.)</p><p>An essential characteristic of B cell ALL/LBL is expression of B cell antigens with absence of T cell antigens; in some cases, myeloid antigens may be expressed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell antigens </strong>- Lymphoblasts of B cell ALL/LBL are almost always positive for the B cell markers CD19, cytoplasmic CD79a, and cytoplasmic CD22; none of these markers alone is specific to the diagnosis, but their positivity in combination or at high intensity strongly supports the diagnosis [<a href="#rid1">1</a>]. In most cases, lymphoblasts are also positive for CD10, CD24, PAX5, and TdT (terminal deoxytransferase); CD20 and CD34 expression is variable, and CD45 may be absent or dim. CD20 expression is present in approximately 40 to 50 percent of B cell ALL cases [<a href="#rid14">14</a>].    </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell antigens </strong>– T cell antigens<strong> </strong>(eg,<strong> </strong>CD3) are negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloid antigens</strong> – Myeloid antigens, such as CD13 and CD33, may be expressed and do not exclude the diagnosis of B cell ALL/LBL; however, expression of myeloperoxidase (MPO) is considered myeloid lineage-defining and excludes the diagnosis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Expression of CD13 and/or CD33 is associated with particular categories of B cell ALL/LBL (eg, <em>ETV6::CBFA2</em>, <em>KMT2A</em>, <em>BCR::ABL1</em>), as described below. (See <a class="local">'Classification of B cell ALL/LBL'</a> below.)</p><p></p><p>Characteristic flow cytometry  (<a class="graphic graphic_figure graphicRef83238" href="/d/graphic/83238.html" rel="external">figure 1</a>) and immunohistochemistry (for TdT) for B cell ALL/LBL are illustrated  (<a class="graphic graphic_picture graphicRef83237" href="/d/graphic/83237.html" rel="external">picture 4</a>).</p><p class="headingAnchor" id="H1091350513"><span class="h2">Cytogenetic/Molecular analysis</span><span class="headingEndMark"> — </span>Conventional chromosomal banding, with or without fluorescence in situ hybridization (FISH), and molecular analysis (for gene rearrangements and patterns of gene expression) should be performed on circulating lymphoblasts, a bone marrow specimen, and/or lymph node material for the classification of B cell ALL/LBL. Fluorescence in situ hybridization (FISH) for t(12;21) can be important, since this rearrangement may be difficult to recognize by karyotyping. Given that the presence of <em>KMT2A</em> and <em>BCR::ABL1</em> fusion genes can dictate prognosis and treatment decisions, FISH testing should be performed for these abnormalities. (See  <a class="medical medical_review" href="/d/html/4482.html" rel="external">"General aspects of cytogenetic analysis in hematologic malignancies"</a> and <a class="local">'Classification of B cell ALL/LBL'</a> below.)</p><p>Testing should also be performed to detect <em>BCR::ABL1</em>-like ALL, ideally by gene expression profiling. Alternative approaches (eg, low-density array [LDA] screening, flow cytometry for <em>CRLF2</em> overexpression, or detection of fusion genes associated with <em>BCR::ABL1</em>-like ALL by cytogenetics/FISH or RNA sequencing) can also be used to identify many cases of <em>BCR::ABL1</em>-like ALL [<a href="#rid5">5,15</a>]. If it is not possible to do this testing in house, send out testing should be performed given the impact of this subtype on prognosis and treatment decisions. (See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'BCR::ABL1-like B cell ALL'</a>.)</p><p>Rearrangement of antigen receptor genes in B cell ALL/LBL is variable and not lineage-specific; as a result, detection of such rearrangements is not a reliable method for assigning lineage. Nearly all cases of B cell ALL have rearrangements of immunoglobulin heavy chain (<em>IGH</em>), but up to 70 percent of cases also have rearrangements of the T cell receptor (<em>TCR</em>) gamma or beta chain genes [<a href="#rid16">16-18</a>].</p><p class="headingAnchor" id="H10"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>B cell ALL/LBL is usually suspected in a child or adult with circulating lymphoblasts and/or painless lymphadenopathy, and may be suspected in the setting of unexplained cytopenias; fatigue, infections, easy or spontaneous bruising/bleeding; constitutional symptoms; bone pain; and/or hepatomegaly or splenomegaly. (See <a class="local">'Clinical features'</a> above.)</p><p>Evaluation should include a complete blood count with differential, examination of the peripheral smear, immunophenotype of peripheral blood or marrow, and bone marrow examination; in some cases, evaluation may include an excisional or needle core biopsy of a lymph node [<a href="#rid1">1</a>]. (See <a class="local">'Pathologic features'</a> above.)</p><p>This material should also be analyzed by cytogenetic and molecular techniques to enable categorization according to the World Health Organization (WHO) classification [<a href="#rid1">1</a>]  (<a class="graphic graphic_table graphicRef110239" href="/d/graphic/110239.html" rel="external">table 1</a>). (See <a class="local">'Classification of B cell ALL/LBL'</a> below.)</p><p>Diagnosis of B cell ALL/LBL requires detection of lymphoblasts with the characteristic immunophenotype in peripheral blood, bone marrow, or other involved tissue; although there is no consensus regarding a minimal proportion of lymphoblasts in bone marrow, the diagnosis of B cell ALL/LBL should be avoided when there are &lt;20 percent lymphoblasts [<a href="#rid1">1</a>].</p><p>Following is the characteristic immunophenotype of B cell ALL/LBL:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>B cell antigens</strong> -<strong> </strong>Lymphoblasts of B cell ALL/LBL are almost always positive for CD19, cytoplasmic CD79a, and cytoplasmic CD22; none of these markers alone is specific to the diagnosis, but their positivity in combination or at high intensity strongly supports the diagnosis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>T cell antigens </strong>– T cell antigens (eg,<strong> </strong>CD3) are negative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloid antigens</strong> – Myeloid antigens, such as CD13 and CD33, may be expressed and do not exclude the diagnosis of B cell ALL/LBL [<a href="#rid1">1</a>]. However, expression of myeloperoxidase (MPO) is considered myeloid lineage-defining, and coexpression of MPO with B lineage antigens excludes the diagnosis of B cell ALL/LBL.</p><p></p><p class="headingAnchor" id="H4039522418"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis of B cell ALL/LBL is described above. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p>The differential diagnosis includes malignant and nonmalignant processes.</p><p class="headingAnchor" id="H3317981581"><span class="h2">Malignant disorders</span><span class="headingEndMark"> — </span>Immunophenotype and cytogenetic/molecular findings are necessary to distinguish B cell ALL/LBL from other leukemias and lymphomas, because morphology alone is not diagnostic.</p><p class="headingAnchor" id="H2839178579"><span class="h3">T cell ALL/LBL</span><span class="headingEndMark"> — </span>Immunophenotyping is required to distinguish T cell ALL/LBL from B cell ALL/LBL. Rearrangement of antigen receptor genes (ie, immunoglobulin [Ig] genes, T cell receptors) is not entirely lineage specific and cannot be used to distinguish between these disorders, as described above. (See <a class="local">'Cytogenetic/Molecular analysis'</a> above.)</p><p>Lymphoblasts of T cell ALL/LBL are typically positive for CD7 and either surface or cytoplasmic CD3; other immunophenotypic characterization of T cell ALL/LBL is discussed separately. Cytogenetic and molecular features of T cell ALL/LBL also are almost entirely different from B cell ALL/LBL. (See  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Evaluation and diagnosis'</a>.)</p><p>T cell ALL/LBL is more likely to be associated with a mediastinal mass; other aspects of the clinical presentation are discussed separately. (See  <a class="medical medical_review" href="/d/html/15773.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H1661742330"><span class="h3">Burkitt lymphoma</span><span class="headingEndMark"> — </span>Typically, the malignant cells of Burkitt lymphoma (BL) have a somewhat different appearance from lymphoblasts in smears, but there is sufficient overlap that this distinction cannot be made reliably, particularly in cases of BL with extensive marrow involvement.</p><p>The diagnosis of BL is based on morphology, immunophenotype, and cytogenetic/molecular features of blood, bone marrow, lymph node, or other tissue. Histology reveals a monomorphic collection of medium-sized cells with basophilic cytoplasm and a high proliferation fraction (often with a "starry sky" appearance and Ki-67+ fraction approaching 100 percent). Compared with B cell ALL/LBL, the malignant cells of BL are generally larger (ie, intermediate-sized oval or round nuclei, dispersed chromatin, several distinct nucleoli, and abundant cytoplasm). Diagnosis of BL relies on immunophenotype (typically a mature germinal center B cell phenotype: CD19+, CD20+, CD10+, surface Ig positive) and detection of a translocation involving chromosome 8q24 and/or <em>MYC</em> rearrangement. By contrast, B lymphoblasts do not express surface Ig and are variably positive for CD10 and CD20.</p><p>Rarely, Burkitt lymphoma may express TdT, and a small subset of B cell ALL/LBL has <em>MYC</em> rearrangements. It is usually possible to distinguish between these two tumors based on immunophenotyping, as Burkitt lymphoma has a mature B cell phenotype and expresses surface light chain, whereas B cell ALL/LBL lacks these features.</p><p>Diagnosis of BL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4700.html" rel="external">"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3550172646"><span class="h3">Other acute leukemias</span><span class="headingEndMark"> — </span>B cell ALL/LBL lymphoblasts may be difficult to distinguish morphologically from other forms of acute leukemia, particularly those that are minimally differentiated:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myeloid leukemia (AML)</strong> – Myeloblasts of AML are immature cells with large nuclei, usually with prominent nucleoli, and a variable amount of pale blue cytoplasm (sometimes with faint granulation and/or Auer rods). AML cells generally stain for myeloperoxidase (MPO) or lysozyme and are generally negative for B and T cell antigens and TdT. Exceptions to this rule are recognized; as an example, AML associated with t(8;21) characteristically expresses PAX5 and CD19 [<a href="#rid19">19</a>] and has been reported to respond to therapy directed against CD19 [<a href="#rid20">20</a>]. Other aspects of the diagnosis of AML are presented separately. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute undifferentiated leukemia (AUL)</strong> – AUL blast cells are morphologically bland and generally indistinguishable from those of B cell ALL/LBL. Distinguishing between these entities depends on immunophenotyping. AUL blasts do not express lineage-specific antigens by flow cytometry or immunohistochemistry; in contrast, B cell ALL/LBL blasts express B lymphoid antigens (and may also express certain myeloid antigens). There is no cytogenetic or molecular finding that is specific for these leukemias. (See  <a class="medical medical_review" href="/d/html/116801.html" rel="external">"Mixed phenotype acute leukemia", section on 'Acute undifferentiated leukemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed phenotype leukemia (MPAL)</strong> – Diagnosis of MPAL requires demonstration of both myeloid- and lymphoid-defining markers by flow cytometry and/or immunohistochemistry and the absence of entity-defining genetic aberrations, such as t(8;21). (See  <a class="medical medical_review" href="/d/html/116801.html" rel="external">"Mixed phenotype acute leukemia", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H1797100451"><span class="h3">Other lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Other lymphoproliferative disorders that may resemble B cell ALL/LBL clinically and/or morphologically can be distinguished by immunophenotype and/or genetic features, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</strong> – CLL/SLL is distinguished from B cell ALL/LBL by a preponderant population of morphologically mature-appearing small lymphocytes with appropriate immunophenotype (expression of B cell antigens CD19, CD20, and CD23; T cell antigen CD5; and low-level monoclonal surface immunoglobulin) in peripheral blood (≥5000/microL) or lymph node, spleen, or other extramedullary tissue. On occasion, a preponderance of small blasts in B cell ALL/LBL may result in a superficial morphologic resemblance to CLL/SLL, but other features cited above readily distinguish these entities. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>B</strong> <strong>prolymphocytic leukemia (PLL)</strong> – PLL is distinguished from B cell ALL/LBL by detection of characteristic prolymphocytes (ie, light chain restriction, bright surface immunoglobulin, expression of B cell antigens CD20, CD22, FMC7, CD79a; absent or weak CD5 and CD23 expression; and no expression of CD11c, CD103, CD10, and CD25) that constitute &gt;55 percent of lymphoid cells in the peripheral blood. (See  <a class="medical medical_review" href="/d/html/4747.html" rel="external">"B cell prolymphocytic leukemia", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mantle cell lymphoma (MCL)</strong> – MCL is distinguished from B cell ALL/LBL by the characteristic histologic appearance (eg, small to medium-sized lymphoid cells, with slightly irregular or "notched" nuclei), immunophenotype (typically expressing CD19, CD20, CD5, and FMC7), nuclear staining for cyclin D1 (BCL1), and t(11;14)(q13;q32) or <em>CCND1-IgH</em> rearrangement. On occasion, blastoid variants of MCL may closely mimic the morphologic appearance of B cell ALL/LBL, but these entities are readily distinguish by the other criteria cited above. (See  <a class="medical medical_review" href="/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis", section on 'Diagnosis and classification'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma cell leukemia </strong>– Plasma cell leukemia may sometimes be composed of relatively small, blast-like cells, but is distinguished from B cell ALL/LBL by its characteristic immunophenotype (eg, positive for CD79a, VS38c, CD138, and CD38) in peripheral blood, bone marrow, or extramedullary tissue, and the presence of monoclonal serum immunoglobulin and/or free light chains. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6646.html" rel="external">"Plasma cell leukemia"</a>.)</p><p></p><p class="headingAnchor" id="H882367290"><span class="h3">Chronic myeloid leukemia (CML) in blast crisis</span><span class="headingEndMark"> — </span>Morphologically, CML is typically manifested as an expanded population of myeloid cells at various stages of differentiation with the Philadelphia chromosome, t(9;22), and <em>BCR::ABL1</em> rearrangement. About 10 percent of blast crisis CML may have a dominant population of lymphoblasts, but in this setting, the Philadelphia chromosome is detected in myeloid cells and basophilia may be present. (See  <a class="medical medical_review" href="/d/html/4543.html" rel="external">"Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2820832764"><span class="h3">Small round blue cell tumors</span><span class="headingEndMark"> — </span>In children, small round blue cell tumors, including Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET) may resemble B cell ALL/LBL morphologically, but these disorders are distinguished by a uniform population of small, round, blue cells with hyperchromatic nuclei and scant cytoplasm; absence of B lymphoid markers; and presence of certain characteristic cytogenetic/molecular findings (eg, t(11;22)(q24;q12), <em>EWSR1::FLI1</em> rearrangement). Diagnosis of small round blue cell tumors and the differential diagnosis of such tumors are discussed separately. (See  <a class="medical medical_review" href="/d/html/7742.html" rel="external">"Epidemiology, pathology, and molecular genetics of Ewing sarcoma", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H2116548452"><span class="h2">Nonmalignant disorders</span><span class="headingEndMark"> — </span>Certain nonmalignant disorders may resemble B cell ALL/LBL morphologically and/or clinically. In adults and children, the following disorders may be included in the differential diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Human immunodeficiency virus (HIV)</p><p class="bulletIndent1"><span class="glyph">●</span>Infectious mononucleosis</p><p class="bulletIndent1"><span class="glyph">●</span>Pertussis</p><p class="bulletIndent1"><span class="glyph">●</span>Osteomyelitis</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis</p><p class="bulletIndent1"><span class="glyph">●</span>Heavy metal toxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Thymoma</p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune diseases (including juvenile rheumatoid arthritis in children)</p><p></p><p>Distinguishing these disorders from B cell ALL/LBL in children and adults is discussed separately. (See  <a class="medical medical_review" href="/d/html/8387.html" rel="external">"Approach to the child with lymphocytosis or lymphocytopenia", section on 'Causes of reactive lymphocytosis'</a> and  <a class="medical medical_review" href="/d/html/104124.html" rel="external">"Approach to the adult with lymphocytosis or lymphocytopenia", section on 'Causes of lymphocytosis'</a>.)</p><p>In infants and very young children, the differential diagnosis also includes hematogones, which are normal developing pre-B cells in peripheral blood or bone marrow. Hematogones show a spectrum of B lymphocyte maturation, including surface immunoglobulin light chain, and display a reproducible pattern of acquisition and loss of normal B cell antigens. In contrast, most malignant cells in B cell ALL/LBL have a single immunophenotype and the spectrum of normal B cell differentiation is absent. (See  <a class="medical medical_review" href="/d/html/8387.html" rel="external">"Approach to the child with lymphocytosis or lymphocytopenia", section on 'Malignant lymphocytosis'</a>.)</p><p class="headingAnchor" id="H3080306655"><span class="h1">CLASSIFICATION OF B CELL ALL/LBL</span><span class="headingEndMark"> — </span>All cases of B cell ALL/LBL should be categorized according to the immunophenotypic and cytogenetic/genetic classification described in the sections that follow. Additional discussion of classification of B cell ALL/LBL is presented separately.(See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"</a>.)</p><p>It is not necessary to distinguish between leukemia versus lymphoma, because they are considered different clinical manifestations of the same disease.</p><p class="headingAnchor" id="H1070011030"><span class="h2">B cell ALL/LBL, NOS</span><span class="headingEndMark"> — </span>B cell ALL/LBL, not otherwise specified (NOS)<strong> </strong>has none of the features that define the various cytogenetic/genetic categories that are described below.</p><p>Typical clinical presentation, pathologic features, and diagnosis of B cell ALL/LBL NOS<strong> </strong>are described above. (See <a class="local">'Clinical features'</a> above and <a class="local">'Pathologic features'</a> above and <a class="local">'Evaluation and diagnosis'</a> above.)</p><p class="headingAnchor" id="H281309529"><span class="h2">Ph+; t(9;22)(q34.1; q11.2); <i>BCR::ABL1</i></span><span class="headingEndMark"> — </span>The Philadelphia (Ph) chromosome, t(9;22), is associated with expression of the <em>BCR::ABL1 </em>oncogene. Although Ph+ ALL was historically considered an adverse feature, its prognostic importance has improved in the era of tyrosine kinase inhibitors [<a href="#rid21">21</a>].</p><p>Ph is detected in approximately one-quarter of adult ALL, but in only 2 to 4 percent of childhood cases; the incidence increases with age, and it is found in 40 to 50 percent of patients ≥60 years old [<a href="#rid22">22-24</a>].</p><p>Ph+ B cell ALL/LBL is defined by chromosomal banding, fluorescence in situ hybridization (FISH), and/or detection of <em>BCR::ABL1 </em>by RT-polymerase chain reaction; approximately one-half of cases express the p210 BCR::ABL1 protein (characteristic of chronic myeloid leukemia) and half express the p190 protein [<a href="#rid25">25</a>]. Ph+ B cell ALL/LBL is often associated with a pre-B immunophenotype (CD19+, CD10+); it is typically positive for TdT and CD25, and there is frequent expression of myeloid antigens [<a href="#rid26">26-29</a>]. However, no specific morphologic or clinical features distinguish Ph+ B cell ALL/LBL from other categories.</p><p>The distinctive management of Ph+ B cell ALL/LBL is discussed separately. (See  <a class="medical medical_review" href="/d/html/16661.html" rel="external">"Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/16841.html" rel="external">"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults"</a>.)</p><p class="headingAnchor" id="H1623729507"><span class="h2">t(v;11q23.3); <i>KMT2A</i>-rearranged</span><span class="headingEndMark"> — </span>This category of B cell ALL/LBL harbors t(v;11q23.3) and a translocation involving <em>KMT2A</em> (formerly called <em>MLL</em>) with one of &gt;100 fusion partners including <em>AFF1</em> (<em>AF4</em>), <em>MLLT1</em> (<em>ENL</em>), or <em>MLLT3</em> (<em>AF9</em>).</p><p>This is the most common category of B cell ALL in infants; it is less common in older children, but it becomes increasingly common in adulthood [<a href="#rid1">1</a>]. The white blood cell (WBC) count is typically increased, frequently &gt;100,000/microL. Central nervous system (CNS) involvement is common and there may be infiltration of other organs, although pure lymphomatous presentations are not typical. </p><p><em>KMT2A</em>-rearranged tumors typically manifest a pro-B immunophenotype (CD19+, CD10-), often with co-expression of the myeloid markers CD15, CD33, and CD68 [<a href="#rid26">26,30</a>]. FISH may be required to diagnose this subtype, as some rearrangements are cytogenetically cryptic [<a href="#rid31">31</a>].</p><p>Leukemias with deletion of 11q23.3 without <em>KMT2A</em> rearrangement are not included in this category. Cases of acute leukemia with <em>KMT2A</em> rearrangement and distinct lymphoblastic and monoblastic populations (by morphology and/or immunophenotyping) should be considered mixed phenotype acute leukemia, as described below. (See <a class="local">'Other acute leukemias'</a> above.)</p><p class="bulletIndent1">B cell ALL with <em>KMT2A</em> rearrangement is associated with a poor prognosis [<a href="#rid27">27,32</a>]. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Structural abnormalities'</a>.)</p><p></p><p class="headingAnchor" id="H2457979285"><span class="h2">t(12;21)(p13.2;q22.1); <i>ETV6::RUNX1</i></span><span class="headingEndMark"> — </span>This category of B cell ALL/LBL is associated with t(12;21) and the <em>ETV6::CBFA2</em> fusion (formerly known as <em>TEL::AML1</em>).</p><p>This subtype is the most common form of B cell ALL/LBL associated with a defining chromosomal rearrangement in children (approximately one-quarter of cases); it is not seen in infants and it is rare in adulthood [<a href="#rid6">6,33</a>]. </p><p>These tumors usually have a pre-B cell immunophenotype (CD19+, CD10+). Absent or dim expression of CD9, CD20, and CD66c is relatively specific for this entity [<a href="#rid28">28,34,35</a>]. The malignant cells are usually CD34+, and they frequently express myeloid-associated antigens (especially CD13) [<a href="#rid36">36</a>]. This form of B cell ALL/LBL is associated with a unique gene expression signature [<a href="#rid37">37</a>]. FISH may be required to detect this disorder, as some rearrangements are cytogenetically cryptic [<a href="#rid38">38</a>].</p><p>B cell ALL/LBL t(12;21)(p12;q22);<em>ETV6::CBFA2</em> is associated with a good prognosis. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Structural abnormalities'</a>.)</p><p class="headingAnchor" id="H1726796445"><span class="h2">Hyperdiploidy</span><span class="headingEndMark"> — </span>Hyperdiploid B cell ALL/LBL has &gt;50 chromosomes, typically without translocations or other structural chromosomal alterations. Hyperdiploid B cell ALL can be detected by conventional karyotyping, FISH, or flow cytometric DNA index [<a href="#rid39">39</a>].</p><p>Hyperdiploid B cell ALL is common in children (≥25 percent of childhood cases), it is not seen in infants, and its frequency decreases among older children. It is uncommon in adulthood (7 to 8 percent) of B cell ALL [<a href="#rid40">40</a>].</p><p>Hyperdiploid B cell ALL/LBL has no distinguishing morphologic or clinical features. The lymphoblasts have a pre-B cell immunophenotype (CD19+, CD10+) and in most cases are CD34+; CD45 is often absent [<a href="#rid28">28</a>]. Chromosomes 21, X, 14, and 4 most commonly show increases in copy number [<a href="#rid41">41</a>].</p><p>The prognostic significance in adults is uncertain, but hyperdiploid B cell ALL has a very favorable prognosis in children. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'High hyperdiploidy'</a>.)</p><p class="headingAnchor" id="H2093046459"><span class="h2">Hypodiploidy</span><span class="headingEndMark"> — </span>Hypodiploid B cell ALL/LBL is characterized by loss of one or more chromosomes.</p><p>About 5 percent of cases of B cell ALL/LBL are hypodiploid, but only 1 percent have &lt;45 chromosomes [<a href="#rid42">42</a>]. The incidence of hypodiploidy is higher in adults.</p><p>The lymphoblasts of hypodiploid B cell ALL/LBL have a pre-B cell immunophenotype (CD19+, CD10+), but there are no other distinctive immunophenotypic or clinical features.</p><p>Hypodiploid B cell ALL cases may be subclassified based on the number of chromosomes into categories with distinctive genetic lesions: near-haploid (23 to 29 chromosomes), low hypodiploid (33 to 39), high hypodiploid (40 to 43), and near-diploid (44 to 46); As examples, near-haploid B cell ALL often has <em>RAS</em> or receptor tyrosine kinase mutations, while most low hypodiploid B cell ALL have loss-of-function mutations of <em>TP53</em> and/or <em>RB1</em>.</p><p>Near-diploid classes are associated with a good prognosis, but all other classes of hypodiploid B cell ALL/LBL are associated with a poor prognosis [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Hypodiploidy'</a>.)</p><p class="headingAnchor" id="H3753991012"><span class="h2">t(5;14)(q31.1;q32.1); <i>IGH::IL3</i></span><span class="headingEndMark"> — </span>In this category, lymphoblasts harbor a translocation between <em>IL3</em> and <em>IGH</em> (immunoglobulin heavy chain).</p><p>This rare disorder accounts for &lt;1 percent of cases of B cell ALL, and it has been reported in both children and adults [<a href="#rid1">1</a>].</p><p>The form of B cell ALL/LBL is often associated with low numbers of circulating lymphoblasts accompanied by asymptomatic eosinophilia; the eosinophils are a reactive population of cells and not part of the malignant clone. Even small numbers of CD19+, CD10+ blasts in a patient with eosinophilia strongly suggests this diagnosis [<a href="#rid1">1</a>].</p><p>The rearrangement between <em>IL3</em> on chromosome 5 and <em>IGH</em> on chromosome 14 causes constitutive overexpression of IL3 [<a href="#rid43">43</a>].</p><p>Prognosis is not considered to be different from other categories of B cell ALL [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H4016248483"><span class="h2">t(1;19)(q23;p13.3); <i>TCF3-PBX1</i></span><span class="headingEndMark"> — </span>The presence of t(1;19) translocation and/or fusion of <em>TCF3</em> (also known as <em>E2A</em>) and <em>PBX1</em> defines this category. <em>TCF3::PBX1</em> translocation generates a fusion protein that acts as a transcriptional activator and also interferes with function of normal TCF3 and PBX1 [<a href="#rid45">45</a>].</p><p>This cytogenetic/genetic abnormality is relatively common in children (approximately 6 percent of B cell ALL), but it is less common in adults [<a href="#rid6">6</a>].</p><p>Lymphoblasts typically have a pre-B phenotype and are CD19+, CD10+, CD9+, express cytoplasmic Mu heavy chain, and are dim or negative for CD34 [<a href="#rid46">46</a>]. This category has no unique morphologic or clinical aspects, but does have a distinct gene expression profile signature [<a href="#rid37">37</a>]. There may be an increased risk of CNS relapse in these patients [<a href="#rid47">47</a>].</p><p>The category of B cell ALL/LBL t(1;19)(q23;p13.3); <em>TCF3::PBX1</em> has no distinctive prognostic significance with contemporary treatment. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Structural abnormalities'</a>.)</p><p>Demonstration of a <em>TCF</em> rearrangement alone is not sufficient to diagnose this category of leukemia, because an alternative translocation of <em>TCF3</em> that involves the <em>HLF</em> gene is associated with t(17;19) and is associated with a dismal prognosis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2610463896"><span class="h2"><i>BCR::ABL1</i>-like (Ph-like)</span><span class="headingEndMark"> — </span>This category is associated with a gene expression signature that resembles that of Ph+ B cell ALL, but the cells lack the characteristic (9;22) translocation and associated <em>BCR::ABL1</em> fusion gene [<a href="#rid15">15</a>].</p><p>The <em>BCR::ABL1</em>-like category accounts for approximately 10 percent of childhood B cell ALL/LBL, but up to one-third of cases in adults [<a href="#rid6">6,48</a>]. (See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'BCR::ABL1-like B cell ALL'</a>.)</p><p>Patients with <em>BCR::ABL1</em>-like B cell ALL/LBL tend to have a high WBC count at presentation. Lymphoblasts have a CD19+, CD10+ phenotype. Cases with <em>CRLF2</em> translocations show high level expression of surface CRLF2 by flow cytometry, but there are no specific immunophenotypic features associated with other molecular abnormalities. Some rearrangements are detectable by conventional karyotype analysis, but others are cryptic [<a href="#rid15">15</a>]. Diagnosis of this condition generally requires gene expression analysis coupled with cytogenetic and molecular diagnostic testing [<a href="#rid49">49</a>].  </p><p>Approximately half of these cases have translocations involving <em>CRLF2</em>, while others have translocations involving tyrosine kinases (eg, <em>JAK2</em>,<em> ABL1</em>, <em>ABL2</em>, <em>PDGFRB</em>, <em>NTRK3</em>, <em>TYK2</em>, <em>CSF1R</em>) or activation of <em>EPOR </em>[<a href="#rid6">6</a>]. A high fraction of these tumors also has mutations in <em>IKZF1</em> [<a href="#rid50">50</a>], a gene that encodes an important transcriptional regulator of lymphoid development. The incidence of specific rearrangements varies by age [<a href="#rid15">15</a>]. CRLF2 rearrangements are the most common alterations across all age groups [<a href="#rid15">15</a>]. <em>ABL</em> fusions are more frequent in children and <em>JAK2</em> rearrangements have an increased incidence in young adults [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma", section on 'BCR::ABL1-like B cell ALL'</a>.)</p><p>This category of B cell ALL/LBL is associated with poor outcomes, and cases with <em>CRLF2</em> translocations have especially poor prognosis [<a href="#rid51">51-57</a>].</p><p class="headingAnchor" id="H1684479060"><span class="h2">iAMP21</span><span class="headingEndMark"> — </span>Amplification of a portion of chromosome 21 is typically detected by FISH probe for <em>RUNX1</em> that reveals ≥5 copies of the gene (or ≥3 extra copies on a single abnormal chromosome 21) [<a href="#rid58">58,59</a>]. This abnormality is less common in adults. B cell ALL/LBL is increased 3000-fold in individuals with constitutional Robertsonian translocation rob(15;21)(q10;q10) due to chromothripsis; this mechanism may also contribute to sporadic cases of iAMP21 [<a href="#rid60">60</a>].</p><p>This entity accounts for approximately 2 percent of B cell ALL, and is usually found in older children, especially those who present with a low WBC count [<a href="#rid1">1,6</a>].</p><p>In most cases, iAMP21 is associated with other chromosomal changes. It is associated with poor prognosis in children, although more intensive therapy may overcome this adverse risk [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Structural abnormalities'</a>.)</p><p class="headingAnchor" id="H3519955084"><span class="h2">Other genetic subtypes</span><span class="headingEndMark"> — </span>Molecular and genetic evaluation of a cohort of nearly 2000 cases of childhood and adult B cell ALL/LBL identified additional distinct genetic subtypes that have yet to be incorporated into the WHO classification [<a href="#rid61">61</a>]. These include subtypes defined by structural rearrangements in the genes <em>DUX4</em>, <em>NUTM1</em>, <em>MEF2D</em>, <em>ZNF384</em>, and <em>MYC</em>, and other genetic aberrations involving <em>PAX5</em> and <em>IZKF1</em>. The most common of these subtypes, defined diverse <em>PAX5</em> alterations, constituted 7 percent of cases in this series and had features associated with high-risk disease in children. Additional studies are needed to evaluate these new genetic subtypes, which are likely to be incorporated into future WHO classifications.</p><p class="headingAnchor" id="H12"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognosis in B cell ALL/LBL is associated with age, clinical features, and cytogenetic/genetic features  (<a class="graphic graphic_table graphicRef71649" href="/d/graphic/71649.html" rel="external">table 2</a>). The role of minimal residual disease testing in assessing response to therapy and prognosis is discussed separately. (See  <a class="medical medical_review" href="/d/html/4519.html" rel="external">"Clinical use of measurable residual disease detection in acute lymphoblastic leukemia"</a> and  <a class="medical medical_review" href="/d/html/4499.html" rel="external">"Detection of measurable residual disease in acute lymphoblastic leukemia/lymphoblastic lymphoma"</a>.) </p><p>Clinical features that are associated with unfavorable prognosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Age (≤1 year or ≥10 years old)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Many infants have translocations involving the <em>KMT2A</em> (<em>MLL</em>) at 11q23, which is associated with a poor prognosis at any age [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older children more often have hyperdiploidy and t(12;21), which confer a better prognosis [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adult B cell ALL/LBL is more often associated with t(9;22) or poor risk t(v;11q23.3) abnormalities, and survival is poorer than in childhood cases [<a href="#rid26">26,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukocyte count ≥50,000/microL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Race (Hispanic or Black) due to genomic variations and socioeconomic factors [<a href="#rid53">53,63,64</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p></p><p>Clinical features that are associated with outcomes in B cell ALL/LBL are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Clinical features'</a>.)</p><p>The relationship between prognosis and cytogenetic abnormalities in ALL is discussed above and separately. (See  <a class="medical medical_review" href="/d/html/4484.html" rel="external">"Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"</a> and  <a class="medical medical_review" href="/d/html/6248.html" rel="external">"Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents", section on 'Cytogenetics'</a>.)</p><p class="headingAnchor" id="H1852756731"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119662.html" rel="external">"Society guideline links: Acute lymphoblastic leukemia"</a>.)</p><p class="headingAnchor" id="H985266"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15789.html" rel="external">"Patient education: Acute lymphoblastic leukemia (ALL) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/685.html" rel="external">"Patient education: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – B cell acute lymphoblastic leukemia/lymphoma (B cell ALL/LBL) is a malignancy of immature B cells that is most common in children (three-quarters of cases are in children &lt;6 years old), but there is a second peak of incidence in adults &gt;60 years old. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1">Leukemia and lymphoma are overlapping clinical presentations of the same disease (ie, B cell ALL/LBL); diagnosis and classification do not distinguish between these entities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Most patients have findings associated with anemia, neutropenia, and/or thrombocytopenia. Symptoms can include fatigue, infections, bleeding, bone pain, arthralgias, or constitutional symptoms. Hepatomegaly, splenomegaly, lymphadenopathy, and/or central nervous system findings may be present. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic features</strong> – The white blood cell (WBC) count may be decreased, normal, or markedly elevated. Peripheral blood smear, bone marrow biopsy, and tissue biopsy demonstrate generally small to medium-sized lymphoblasts with uniform appearance and scant cytoplasm. (See <a class="local">'Morphology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Includes complete blood count with differential count, examination of the blood smear, immunophenotype of blood or marrow, and bone marrow examination; lymph node biopsy may be included for some patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – B cell ALL/LBL is usually suspected in a child or adult with circulating lymphoblasts and/or painless lymphadenopathy; it may be suspected in the setting of unexplained cytopenias or associated symptoms, constitutional symptoms, bone pain, and/or organomegaly. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis requires demonstration of B lymphoblasts with the characteristic immunophenotype in blood, bone marrow, or other involved tissue (see <a class="local">'Evaluation and diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>B cell antigens are expressed: </strong>CD19, cytoplasmic CD79a, and/or cytoplasmic CD22; although the individual markers are not specific for B cell ALL/LBL, their positivity in combination or with high intensity strongly supports the diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell antigens are not expressed: </strong>T cell antigens<strong> </strong>(eg,<strong> </strong>CD3) are negative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myeloid antigens may be expressed:</strong> CD13 and/or CD33 may be expressed and do not exclude the diagnosis of B cell ALL/LBL; in contrast, myeloperoxidase (MPO) is considered myeloid lineage-defining, and its expression excludes the diagnosis of B cell ALL/LBL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – All cases of B cell ALL/LBL should be categorized according to the World Health Organization (WHO) classification, based on cytogenetic/genetic features. (See <a class="local">'Classification of B cell ALL/LBL'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Includes other leukemias (eg, T cell ALL/LBL, Burkitt lymphoma, other acute leukemias, chronic myeloid leukemia) and lymphoproliferative disorders, as well as certain nonmalignant processes, including infectious and reactive/inflammatory processes, and hematogones (normal developing pre-B cells in infants and very young children). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Outcomes are associated with age, WBC count, race, male sex, and cytogenetic/genetic features  (<a class="graphic graphic_table graphicRef71649" href="/d/graphic/71649.html" rel="external">table 2</a>). (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3927903081"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Arnold S Freedman, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Redaelli A, Laskin BL, Stephens JM, et al. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl) 2005; 14:53.</a></li><li><a class="nounderline abstract_t">Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.</a></li><li><a class="nounderline abstract_t">Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.</a></li><li><a class="nounderline abstract_t">Jain N, Roberts KG, Jabbour E, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood 2017; 129:572.</a></li><li><a class="nounderline abstract_t">Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013; 381:1943.</a></li><li><a class="nounderline abstract_t">Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 2013; 45:1226.</a></li><li><a class="nounderline abstract_t">Qian M, Cao X, Devidas M, et al. TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 2018; 36:591.</a></li><li><a class="nounderline abstract_t">Ziino O, Rondelli R, Micalizzi C, et al. Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experience. Haematologica 2006; 91:139.</a></li><li><a class="nounderline abstract_t">Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1006.</a></li><li><a class="nounderline abstract_t">Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013; 45:1494.</a></li><li><a class="nounderline abstract_t">Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol 2011; 152:441.</a></li><li><a class="nounderline abstract_t">Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981; 47:553.</a></li><li><a class="nounderline abstract_t">Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009; 113:6330.</a></li><li><a class="nounderline abstract_t">Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005.</a></li><li><a class="nounderline abstract_t">Kitchingman GR, Rovigatti U, Mauer AM, et al. Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood 1985; 65:725.</a></li><li><a class="nounderline abstract_t">Tawa A, Hozumi N, Minden M, et al. Rearrangement of the T-cell receptor beta-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood. N Engl J Med 1985; 313:1033.</a></li><li><a class="nounderline abstract_t">Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990; 8:431.</a></li><li><a class="nounderline abstract_t">Walter K, Cockerill PN, Barlow R, et al. Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5. Oncogene 2010; 29:2927.</a></li><li><a class="nounderline abstract_t">Plesa A, Labussière-Wallet H, Hayette S, et al. Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19. Haematologica 2019; 104:e487.</a></li><li><a class="nounderline abstract_t">Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014; 28:1467.</a></li><li><a class="nounderline abstract_t">Ribeiro RC, Abromowitch M, Raimondi SC, et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 1987; 70:948.</a></li><li><a class="nounderline abstract_t">Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 2010; 115:206.</a></li><li><a class="nounderline abstract_t">Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371:1030.</a></li><li><a class="nounderline abstract_t">Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991; 78:2411.</a></li><li><a class="nounderline abstract_t">Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.</a></li><li><a class="nounderline abstract_t">Pui CH, Behm FG, Downing JR, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12:909.</a></li><li><a class="nounderline abstract_t">Hrusák O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16:1233.</a></li><li><a class="nounderline abstract_t">Paietta E, Racevskis J, Neuberg D, et al. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia 1997; 11:1887.</a></li><li><a class="nounderline abstract_t">Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:3768.</a></li><li><a class="nounderline abstract_t">Othman MA, Grygalewicz B, Pienkowska-Grela B, et al. Novel Cryptic Rearrangements in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Involving the MLL Gene. J Histochem Cytochem 2015; 63:384.</a></li><li><a class="nounderline abstract_t">Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359:1909.</a></li><li><a class="nounderline abstract_t">Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13:6.</a></li><li><a class="nounderline abstract_t">Borowitz MJ, Rubnitz J, Nash M, et al. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 1998; 12:1764.</a></li><li><a class="nounderline abstract_t">De Zen L, Orfao A, Cazzaniga G, et al. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification. Leukemia 2000; 14:1225.</a></li><li><a class="nounderline abstract_t">Baruchel A, Cayuela JM, Ballerini P, et al. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br J Haematol 1997; 99:101.</a></li><li><a class="nounderline abstract_t">Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133.</a></li><li><a class="nounderline abstract_t">Romana SP, Le Coniat M, Berger R. t(12;21): a new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer 1994; 9:186.</a></li><li><a class="nounderline abstract_t">Martin PL, Look AT, Schnell S, et al. Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1996; 18:113.</a></li><li><a class="nounderline abstract_t">Mrózek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23:991.</a></li><li><a class="nounderline abstract_t">Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer 2007; 46:684.</a></li><li><a class="nounderline abstract_t">Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110:1112.</a></li><li><a class="nounderline abstract_t">Grimaldi JC, Meeker TC. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 1989; 73:2081.</a></li><li><a class="nounderline abstract_t">Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med 2015; 373:1541.</a></li><li><a class="nounderline abstract_t">LeBrun DP. E2A basic helix-loop-helix transcription factors in human leukemia. Front Biosci 2003; 8:s206.</a></li><li><a class="nounderline abstract_t">Borowitz MJ, Hunger SP, Carroll AJ, et al. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood 1993; 82:1086.</a></li><li><a class="nounderline abstract_t">Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23:1406.</a></li><li><a class="nounderline abstract_t">Tran TH, Loh ML. Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:561.</a></li><li><a class="nounderline abstract_t">Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv 2020; 4:218.</a></li><li><a class="nounderline abstract_t">Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22:153.</a></li><li><a class="nounderline abstract_t">Boer JM, Koenders JE, van der Holt B, et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica 2015; 100:e261.</a></li><li><a class="nounderline abstract_t">Boer JM, Marchante JR, Evans WE, et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica 2015; 100:e354.</a></li><li><a class="nounderline abstract_t">Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312.</a></li><li><a class="nounderline abstract_t">Ensor HM, Schwab C, Russell LJ, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011; 117:2129.</a></li><li><a class="nounderline abstract_t">Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012; 26:2245.</a></li><li><a class="nounderline abstract_t">van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122:2622.</a></li><li><a class="nounderline abstract_t">Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013; 31:e413.</a></li><li><a class="nounderline abstract_t">Harrison CJ, Moorman AV, Schwab C, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2014; 28:1015.</a></li><li><a class="nounderline abstract_t">Heerema NA, Carroll AJ, Devidas M, et al. Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. J Clin Oncol 2013; 31:3397.</a></li><li><a class="nounderline abstract_t">Li Y, Schwab C, Ryan SL, et al. Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 2014; 508:98.</a></li><li><a class="nounderline abstract_t">Gu Z, Churchman ML, Roberts KG, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019; 51:296.</a></li><li><a class="nounderline abstract_t">Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994; 84:1603.</a></li><li><a class="nounderline abstract_t">Yang JJ, Cheng C, Devidas M, et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011; 43:237.</a></li><li><a class="nounderline abstract_t">Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012; 30:751.</a></li></ol></div><div id="topicVersionRevision">Topic 4686 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15698386" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23086753" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27919910" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23523389" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013638" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29300620" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434385" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute lymphoblastic leukemia in children with associated genetic conditions other than Down's syndrome. The AIEOP experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684604" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24141364" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21210776" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6938236" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703706" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207766" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918594" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3930961" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rearrangement of the T-cell receptor beta-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307988" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20208555" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31197067" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24441288" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307953" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897583" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A population-based cytogenetic study of adults with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18358930" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1932753" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10191766" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164041" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12094248" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antigen expression patterns reflecting genotype of acute leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9369422" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850020" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25699572" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Novel Cryptic Rearrangements in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Involving the MLL Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057554" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049061" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The role of TEL fusion genes in pediatric leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9823952" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10914546" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9359509" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086872" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7515661" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : t(12;21): a new recurrent translocation in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846121" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of fluorescence in situ hybridization, cytogenetic analysis, and DNA index analysis to detect chromosomes 4 and 10 aneuploidy in pediatric acute lymphoblastic leukemia: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19825449" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cytogenetics and molecular genetics of acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431878" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473063" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2499362" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465987" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute Lymphoblastic Leukemia in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700034" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : E2A basic helix-loop-helix transcription factors in human leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8353275" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282835" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913529" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ph-like acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31935290" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22897847" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25769542" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26045294" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139093" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106984" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22484421" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974192" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835704" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166298" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940221" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24670643" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30643249" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068949" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297632" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291082" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
